ABOUT THIS CONFERENCE
GPCR-Targeted Therapeutics, the second GPCR day and
a half conference of our back-to-back GPCR conferences at this event, will
focus on GPCR-targeted compounds progressing beyond the discovery phase. Case
studies of drug candidates, including allosteric modulators, will highlight
optimization strategies and pharmacology issues to consider during development.
Drug candidates being developed for therapeutic areas such as cancer, diabetes,
cardiac disease, central nervous system disorders, inflammation and pain will
be presented.
SUGGESTED EVENT PACKAGE:
September 23: Practical Aspects of Structure-Based Drug Discovery with GPCRs Short Course 2
September 23: Allosteric Modulators of GPCRs Short Course 4
September 24 - 25: GPCR-Based Drug Discovery Conference
September 25 - 26: GPCR-Targeted Therapies Conference
Day 1 | Day 2 | Download Brochure
Wednesday, September 25
11:50 am Registration
1:30 pm Chairperson’s Opening Remarks
1:40 PLENARY KEYNOTE PRESENTATION: Towards a Patient-Based
Drug Discovery
Stuart L. Schreiber, Ph.D., Director, Chemical Biology and
Founding Member, Broad Institute of Harvard and MIT; Howard Hughes Medical
Institute Investigator; Morris Loeb Professor of Chemistry and Chemical
Biology, Harvard University
3:10 Refreshment Break in the Exhibit Hall with Poster Viewing
4:00 FEATURED SPEAKER: Something Old, Something New, Something
Borrowed, Something Glu: Lessons Learned in the
Design of Ligands for Metabotropic
Glutamate Receptors
Dario Doller, Ph.D., Director,
Discovery Chemistry & DMPK, Lundbeck Research USA
4:30 Sponsored Presentations (Opportunities Available)
5:00 Advancing GPCR-Targeted Allosteric
Modulators as Novel Therapeutics for Severe CNS Disorders
Sylvain Celanire, Ph.D., former
Associate Research Director, Medicinal Chemistry, Addex;
Independent Pharmaceutical Professional
5:30 Novel mGlu4 Positive Allosteric
Modulators for the Treatment of Parkinson’s Disease
Corey Hopkins, Ph.D., Research Assistant Professor,
Pharmacology, Vanderbilt University
6:00 Technology Combination to Address GPCR
Allosteric Modulator Drug Discovery Pitfalls
Stephan Schann, Ph.D., Head,
Research, Domain Therapeutics, SA
6:30 Close of Day
Day 1 | Day 2 | Download Brochure